Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kezar Life Sciences (KZR) Cash & Equivalents (2021 - 2025)

Kezar Life Sciences (KZR) has disclosed Cash & Equivalents for 5 consecutive years, with $71.9 million as the latest value for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 72.17% year-over-year to $71.9 million; the TTM value through Dec 2025 reached $71.9 million, up 72.17%, while the annual FY2025 figure was $71.9 million, 72.17% up from the prior year.
  • Cash & Equivalents hit $71.9 million in Q4 2025 for Kezar Life Sciences, up from $38.9 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $105.4 million in Q2 2022 and bottomed at $22.9 million in Q1 2021.
  • Average Cash & Equivalents over 5 years is $43.2 million, with a median of $36.6 million recorded in 2023.
  • Year-over-year, Cash & Equivalents surged 299.47% in 2022 and then plummeted 73.33% in 2023.
  • Kezar Life Sciences' Cash & Equivalents stood at $62.9 million in 2021, then crashed by 35.66% to $40.5 million in 2022, then fell by 12.27% to $35.5 million in 2023, then rose by 17.63% to $41.7 million in 2024, then surged by 72.17% to $71.9 million in 2025.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $71.9 million, $38.9 million, and $34.4 million for Q4 2025, Q3 2025, and Q2 2025 respectively.